[et_pb_section fb_built=”1″ theme_builder_area=”post_content” _builder_version=”4.27.5″ _module_preset=”default” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on” da_disable_devices=”off|off|off”][et_pb_row _builder_version=”4.27.5″ _module_preset=”default” theme_builder_area=”post_content”][et_pb_column _builder_version=”4.27.5″ _module_preset=”default” type=”4_4″ theme_builder_area=”post_content”][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” theme_builder_area=”post_content” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
MONTREAL<\/span>,\u00a0<\/span>Sept. 2, 2026<\/span> – ISOLOGIC Innovative Radiopharmaceuticals officially inaugurated its new Lachine facilities yesterday, Tuesday, September 1, during a ribbon-cutting ceremony attended by employees, partners, clients and elected officials. The\u00a0<\/span>$30-million investment<\/b>, announced in 2024, marks an important milestone in the advancement of nuclear medicine in Canada. It will increase the country’s capacity to produce essential radiopharmaceuticals while helping ensure a more reliable supply for healthcare institutions across Canada.<\/span><\/p>\n Radiopharmaceuticals play a critical role in the diagnosis and treatment of many serious diseases, including several forms of\u00a0cancer<\/b>,\u00a0cardiovascular disease<\/b>, neurological conditions such as\u00a0Alzheimer’s disease<\/b>, as well as a range of\u00a0bone disorders<\/b>. By enabling earlier and more precise diagnoses and more targeted treatments, they directly contribute to better patient care and outcomes.<\/span><\/p>\n